Abstract
Abstract
 Introduction and objectives: The treatment of dyslipidemia over 75 years old is not well elucidated, due to the non-inclusion in large randomized clinical trials. Elderly people develop atherosclerosis more often and the worldwide population shows greater longevity. To evaluate the efficacy and safety of statin in very elderly people. Methods: The patients were divided into two groups: over 75 years (very elderly) and up to 75 years (control group). We evaluated: coronary artery disease (CAD); stroke; clearance of creatinine; creatine phosphokinase (CPK) and transaminase (ALT, AST) levels; lipid profile; type, dosage, and time using a statin. Results: The sample of 120 patients, 53,2% male, age 74.1 (±11.1) years, 82.3 very elderly, and 64.9 years in the control group. The total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL-C) in very elderly and control were 162 and 166 (p=ns), 84 and 90 (p=ns), 52.5 and 47 mg/dL (p=0.07), respectively. CAD and stroke, respectively 52.5 and 78.8% (p=0.007), and 18.6 and 7.7% (p=0.09). The time using a statin and the number of drugs taken were the same in the groups. The CPK and ALT levels were 97 and 110 (p=ns) and 16.5 and 20 U/L (p=0.004), respectively. There was no statin dose reduction in the elderly group despite the higher proportion of clinical comorbidities or renal dysfunction. Conclusions: The statin treatment in very elderly patients is effective and safe. The increased risk of CAD and stroke in elderly people corroborate the importance of statin use in this age group.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Arquivos Médicos dos Hospitais e da Faculdade de Ciências Médicas da Santa Casa de São Paulo
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.